Efalizumab for Eczema

Inclusion Criteria:

Adults (18 years or older) with atopic dermatitis with 5% or more body surface area involvement
Investigator Global Assessment (IGA) score of "moderate" or worse
In general good health with well-controlled medical problems
Ability to provide written informed consent and comply with study assessments for the full duration of the study.
If a female of childbearing potential, a negative pregnancy test and commitment to the use of two forms of effective contraception (birth control) for the duration of the study are necessary.
If a non-sterile male, commitment to the use of two forms of effective contraception (birth control) for the duration of the study is necessary.
Normal platelet count

Exclusion Criteria:

Patients with known hypersensitivity to efalizumab or any of its components
Pregnancy or lactation
Patients receiving immunosuppressive agents
Prior enrollment in the study
Participation in another simultaneous medical investigation or trial
IGA score of "mild," "almost clear" or "clear"
Systemic therapy for atopic dermatitis, phototherapy or topical therapy (other than moisturizer) within 1 week
Medical condition which would make use of efalizumab unsafe; would limit compliance with study requirements; or would limit accurate assessment of efficacy.
Ongoing, active, serious infection
History of malignancy (except excised basal or squamous cell carcinoma of the skin)